Advertisement

Peripheral Nerve Disorders

  • Mustafa A. M. SalihEmail author
  • Hamid Azzedine
Chapter
  • 80 Downloads

Abstract

A nerve is composed of axon (neural tissue) and connective tissue. Each axon in myelinated nerve fibers is surrounded by the endoneurium. Groups of nerve fibers form fascicles, surrounded by the perineurium, and groups of fascicles are surrounded by the internal and external epineurium. Impairments of the peripheral nervous system (PNS) lead to peripheral neuropathies that could be whether acquired (traumatic, drug toxicity, infection, etc.) or inherited, due to genetic abnormalities.

Supplementary material

Video 41.1

A 4-year-old girl, with acute lymphoblastic leukemia (ALL), who developed toxicity following vincristine therapy (Fig. 41.3a, b). She could walk after 7 months, and the video, taken 9 months later, shows normal gait (MOV 17021 kb)

Video 41.2

Resuming normal gait in a 10-year-old boy who had Guillain-Barré syndrome a year ago. During the acute illness, he required ventilation for 22 days (AVI 2441 kb)

Video 41.3

An 11-year-old boy with peripheral nervous system vasculitis associated with Churg-Strauss syndrome (Fig. 41.9). The video shows the asymmetric involvement of the lower limbs with right foot drop and high steppage gait (MOV 1567 kb)

Video 41.4

High steppage gait, pes planus, and foot drop in 2.5-year-old twins who have CMT4A due to GDAP1 gene mutation (AVI 9962 kb)

References

  1. 1.
    Salih MA. Peripheral nerve disorders. In: Textbook of clinical pediatrics. Berlin: Springer; 2012. p. 3475–91.Google Scholar
  2. 2.
    Jung KH, Hyun PS. Sciatic nerve injection injury. J Int Med Res. 2014;42(4):887–97.CrossRefGoogle Scholar
  3. 3.
    Namate C, Shabana M, Mumba P, Chimangeni S, Prime M, Cashman J. Aetiology of acquired ‘drop foot’ deformity in Malawian children: a case series of 50 patients. Trop Doct. 2012;42(4):229.PubMedCrossRefGoogle Scholar
  4. 4.
    Griffith AH. The role of immunization in the control of diphtheria. Dev Biol Stand. 1979;43:3–13.PubMedGoogle Scholar
  5. 5.
    Byard RW. Diphtheria—‘The strangling angel’ of children. J Forensic Leg Med. 2013;20(2):65–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Kanwal SK, Yadav D, Chhapola V, Kumar V. Post-diphtheritic neuropathy: a clinical study in paediatric intensive care unit of a developing country. Trop Doct. 2012;42(4):195–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Manikyamba D, Satyavani A, Deepa P. Diphtheritic polyneuropathy in the wake of resurgence of diphtheria. J Pediatr Neurosci. 2014;10(4):331–4.CrossRefGoogle Scholar
  8. 8.
    Mateen FJ, Bahl S, Khera A, Sutter RW. Detection of diphtheritic polyneuropathy by acute flaccid paralysis surveillance. India Emerg Infect Dis. 2013;19(9):1368–73.PubMedGoogle Scholar
  9. 9.
    Zasada A. Corynebacterium diphtheriae infections currently and in the past. Przegl Dermatol. 2014;69(3):439–44.Google Scholar
  10. 10.
    Jablonka A, Behrens GM, Stange M, Dopfer C, Grote U, Hansen G, Schmidt RE, Happle C. Tetanus and diphtheria immunity in refugees in Europe in 2015. Infection. 2016;19:1–8.Google Scholar
  11. 11.
    Salih MAM, Suliman GI, Hassan HS. Complications of diphtheria seen during the 1978 outbreak in Khartoum. Ann Trop Paediatr. 1981;1:97–101.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Salih MAM, Suliman GI, Hassan HS. Unusual sites of diphtheritic membrane and cervical oedema. SudanJPaediatr. 1984;3:52–62.Google Scholar
  13. 13.
    Salih MAM. A clinical profile of diphtheria in Sudanese children. Sudan J Paediatr. 1986;5:31–6.Google Scholar
  14. 14.
    Salih MAM, El Hakeem HS, Suliman GI, Khatim AS. An epidemiological study of the 1978 outbreak of diphtheria in Khartoum province. J Trop Pediatr. 1985;31:8–12.PubMedCrossRefGoogle Scholar
  15. 15.
    Logina I, Donaghy M. Diphtheritic polyneuropathy: a clinical study and comparison with Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 1999;67(4):433–8.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Loevinsohn BP. The changing age structure of diphtheria patients: evidence for the effectiveness of EPI in the Sudan. Bull World Health Organ. 1990;68(3):353–7.PubMedPubMedCentralGoogle Scholar
  17. 17.
    WHO—World Health Organization. Weekly epidemiological record; WHO [Internet] 2015, n° 36, 90th year, p. 461–476. Washington: The Organization. http://www.who.int/wer/2015/wer9036.pdf. Accessed 7 Oct 2016.
  18. 18.
    Santos SD, Penna GO, Costa MD, Natividade MS, Teixeira MG. Leprosy in children and adolescents under 15 years old in an urban centre in Brazil. Mem Inst Oswaldo Cruz. 2016;111(6):359–64.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Schreuder PA, Noto S, Richardus JH. Epidemiologic trends of leprosy for the 21st century. Clin Dermatol. 2016;34:24–31.PubMedCrossRefGoogle Scholar
  20. 20.
    Cook MJ. Lyme borreliosis: a review of data on transmission time after tick attachment. Int J Gen Med. 2015;8:1–8.  https://doi.org/10.2147/IJGM.S73791.CrossRefPubMedGoogle Scholar
  21. 21.
    Centers for Disease Control and Prevention (CDC). Lyme disease data. September 24, 2015. http://www.cdc.gov/lyme/stats/index.html?s_cid=cs_281. Accessed 8 Oct 2016.
  22. 22.
    Centers for Disease Control and Prevention (CDC). Lyme disease—United States, 2003–2005. Morb Mortal Wkly Rep. 2007;56(23):573.Google Scholar
  23. 23.
    Huppertz HI. Childhood Lyme borreliosis in Europe. Eur J Pediatr. 1990;149(12):814–21.PubMedCrossRefGoogle Scholar
  24. 24.
    Hehir MK 2nd, Logigian EL. Infectious neuropathies. Continuum (Minneapolis, Minn.). 2014;20(5 Peripheral Nervous System Disorders):1274–92.Google Scholar
  25. 25.
    Agarwal R, Sze G. Neuro-lyme disease: MR imaging findings. Radiology. 1999;253:167–73.CrossRefGoogle Scholar
  26. 26.
    Dersch R, Hottenrott T, Schmidt S, Sommer H, Huppertz HI, Rauer S, Meerpohl JJ. Efficacy and safety of pharmacological treatments for Lyme neuroborreliosis in children: a systematic review. BMC Neurol. 2016;16(1):189.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Hendaus MA, Qaqish RM, Alhammadi AH. Neurobrucellosis in children. Asian Pac J Trop Biomed. 2015;5(2):158–61.CrossRefGoogle Scholar
  28. 28.
    Salih MA, Abdel-Gader AM, Al-Jarallah AA, Kentab AY, Gadelrab MO, Alorainy IA, et al. Infectious and inflammatory disorders of the circulatory systems as risk factors for stroke in Saudi children. Saudi Med J. 2006;27(Suppl 1):S41–52.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Wilmshurst JM. Diagnosis and management of pediatric peripheral neuropathies in resource-poor settings. Future Neurol. 2013;8(2):133–48.CrossRefGoogle Scholar
  30. 30.
    Kandula T, Park SB, Cohn RJ, Krishnan AV, Farrar MA. Pediatric chemotherapy induced peripheral neuropathy: a systematic review of current knowledge. Cancer Treat Rev. 2016;50:118–28.PubMedCrossRefGoogle Scholar
  31. 31.
    Lavoie SE, Li L, Chiang C, Thomas K, Hutchinson RJ, Wells EM, et al. Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. J Peripher Nerv Syst. 2015;20(1):37–46.CrossRefGoogle Scholar
  32. 32.
    Lanphear BP, Lowry JA, Ahdoot S, Baum CR, Bernstein AS, Bole A, et al. Prevention of childhood lead toxicity. Pediatrics. 2016;20:e20161493.Google Scholar
  33. 33.
    Hamad MH, Adeel AA, Alhaboob AAN, Ashri AM, Salih MA. Acute poisoning in a child following topical treatment of head lice (pediculosis capitis) with an organophosphate pesticide. Sudan J Paediatr. 2016;16(1):63–6.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Madhusudanan M, Menon MK, Ummer K, Radhakrishnanan K. Clinical and etiological profile of tropical ataxic neuropathy in Kerala. South India Eur Neurol. 2007;60(1):21–6.CrossRefGoogle Scholar
  35. 35.
    BMJ Best Practice. Guillain Barre Syndrome. 2016 http://bestpractice.bmj.com/best-practice/monograph-pdf/176.pdf. Accessed 13 Oct 2016.
  36. 36.
    Roodbol J, de Wit MC, Walgaard C, de Hoog M, Catsman-Berrevoets CE, Jacobs BC. Recognizing Guillain-Barre syndrome in preschool children. Neurology. 2011;76(9):807–10.PubMedCrossRefGoogle Scholar
  37. 37.
    Dimachkie MM, Barohn RJ. Guillain-Barre syndrome and variants. Neurol Clin. 2013;31(2):491–510.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Babiker MOE. The boy who stopped walking. Sudan J Paediatr. 2015;15(1):65–8.Google Scholar
  39. 39.
    Nishimoto Y, Susuki K, Yuki N. Serologic marker of acute motor axonal neuropathy in childhood. Pediatr Neurol. 2008;39(1):67–70.PubMedCrossRefGoogle Scholar
  40. 40.
    Schessl J, Koga M, Funakoshi K, Kirschner J, Muellges W, Weishaupt A, et al. Prospective study on anti-ganglioside antibodies in childhood Guillain-Barré syndrome. Arch Dis Child. 2007;92(1):48–52.PubMedCrossRefGoogle Scholar
  41. 41.
    Maloney JA, Mirsky DM, Messacar K, Dominguez SR, Schreiner T, Stence NV. MRI findings in children with acute flaccid paralysis and cranial nerve dysfunction occurring during the 2014 enterovirus D68 outbreak. Am J Neuroradiol. 2015;36(2):245–50.PubMedCrossRefGoogle Scholar
  42. 42.
    Adeel AAA. Spinal cord schistosomiasis. Sudan J Paediatr. 2015;15(2):23–8.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Hughes RAC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014;(9):CD002063.  https://doi.org/10.1002/14651858.CD002063.pub6.
  44. 44.
    Hughes RAC, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2012;(8):CD001446.  https://doi.org/10.1002/14651858.CD001446.pub4.
  45. 45.
    Korinthenberg R, Schessl J, Kirschner J, Mönting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics. 2005;116(1):8–14.PubMedCrossRefGoogle Scholar
  46. 46.
    Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. The Lancet. 2016;388(10045):717–27.CrossRefGoogle Scholar
  47. 47.
    Finsterer J. Systemic and non-systemic vasculitis affecting the peripheral nerves. Acta Neurol Belg. 2009;109(2):100–13.PubMedGoogle Scholar
  48. 48.
    Blaes F. Diagnosis and therapy for peripheral vasculitic neuropathy. In: Systemic vasculitides: current status and perspectives 2016. Cham: Springer International Publishing; 2016. p. 259–80.Google Scholar
  49. 49.
    Said G, Lacroix C. Primary and secondary vasculitic neuropathy. J Neurol. 2005;252(6):633–41.PubMedCrossRefGoogle Scholar
  50. 50.
    Agadi JB, Raghav G, Mahadevan A, Shankar SK. Usefulness of superficial peroneal nerve/peroneus brevis muscle biopsy in the diagnosis of vasculitic neuropathy. J Clin Neurosci. 2012;19(10):1392–6.PubMedCrossRefGoogle Scholar
  51. 51.
    Blaes F. Diagnosis and therapeutic options for peripheral vasculitic neuropathy. Ther Adv Musculoskelet Dis. 2015;7(2):45–55.  https://doi.org/10.1177/1759720X14566617.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Azzedine H, Senderek J, Rivolta C, Chrast R. Molecular genetics of charcot-marie-tooth disease: from genes to genomes. Mol Syndromol. 2012;3(5):204–14.  https://doi.org/10.1159/000343487. Epub 2012 Oct 12CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Azzedine H, Durosier G, Tazir M, et al. Autosomal recessive Charcot-Marie-Tooth families linked to the 1q21 locus. 51st annual meeting of the American Society of Human Genetics, San Diego (USA): 13th–18th October 2001. Abstract in: Am J Hum Genet 2001;69(Suppl):1911.Google Scholar
  54. 54.
    Mathis S, Goizet C, Tazir M, Magdelaine C, Lia AS, Magy L, Vallat JM. Charcot-Marie-Tooth diseases: an update and some new proposals for the classification. J Med Genet. 2015;52(10):681–90.PubMedCrossRefGoogle Scholar
  55. 55.
    Barreto LC, Oliveira FS, Nunes PS, de França CI, Garcez CA, Goes GM, Neves EL, de Souza SQ, de Souza AA. Epidemiologic study of Charcot-Marie-Tooth disease: a systematic review. Neuroepidemiology. 2016;46(3):157–65.PubMedCrossRefGoogle Scholar
  56. 56.
    Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth’s disease. Clin Genet. 1974;6(2):98–118.PubMedCrossRefGoogle Scholar
  57. 57.
    Martin JJ, Brice A, Van Broeckhoven C. 4th workshop of the European CMT-Consortium—62nd ENMC international workshop: rare forms of Charcot-Marie-Tooth disease and related disorders. 16–18 October 1998, Soestduinen, The Netherlands. Neuromuscul Disord. 1999;9(4):279–87.CrossRefGoogle Scholar
  58. 58.
    Laššuthová P, ŠafkaBrožková D, Krůtová M, et al. Improving diagnosis of inherited peripheral neuropathies through gene panel analysis. Orphanet J Rare Dis. 2016;11(1):118.  https://doi.org/10.1186/s13023-016-0500-5.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Ylikallio E, Woldegebriel R, Tumiati M, Isohanni P, Ryan MM, Stark Z, Walsh M, Sawyer SL, Bell KM, Oshlack A, Lockhart PJ, Shcherbii M, Estrada-Cuzcano A, Atkinson D, Hartley T, Tetreault M, Cuppen I, van der Pol WL, Candayan A, Battaloglu E, Parman Y, van Gassen KLI, van den Boogaard MH, Boycott KM, Kauppi L, Jordanova A, Lönnqvist T, Tyynismaa H. MCM3AP in recessive Charcot-Marie-Tooth neuropathy and mild intellectual disability. Brain. 2017;140(8):2093–103.PubMedCrossRefGoogle Scholar
  60. 60.
    Karakaya M, Mazaheri N, Polat I, Bharucha-Goebel D, Donkervoort S, Maroofian R, Shariati G, Hoelker I, Monaghan K, Winchester S, Zori R, Galehdari H, Bönnemann CG, Yis U, Wirth B. Biallelic MCM3AP mutations cause Charcot-Marie-Tooth neuropathy with variable clinical presentation. Brain. 2017;140(10):e65.  https://doi.org/10.1093/brain/awx222.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Baets J, Deconinck T, De Vriendt E, Zimon M, Yperzeele L, Van Hoorenbeeck K, et al. Genetic spectrum of hereditary neuropathies with onset in the first year of life. Brain. 2011;134:266476.Google Scholar
  62. 62.
    Bird TD. Charcot-Marie-Tooth Hereditary Neuropathy Overview. 1998 Sep 28 [Updated 2016 Sep 1]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2017. 2016. https://www.ncbi.nlm.nih.gov/books/NBK1358/
  63. 63.
    Bird TD. Hereditary Neuropathy with Liability to Pressure Palsies. 1998 Sep 28 [Updated 2014 Sep 25]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle;1993–2016. 2014. https://www.ncbi.nlm.nih.gov/books/NBK1392/
  64. 64.
    Azzedine H, Ravisé N, Verny C, Gabrëels-Festen A, Lammens M, Grid D, Vallat JM, Durosier G, Senderek J, Nouioua S, Hamadouche T, Bouhouche A, Guilbot A, Stendel C, Ruberg M, Brice A, Birouk N, Dubourg O, Tazir M, LeGuern E. Spine deformities in Charcot-Marie-Tooth 4C caused by SH3TC2 gene mutations. Neurology. 2006;67(4):602–6.PubMedCrossRefGoogle Scholar
  65. 65.
    Bouhouche A, Birouk N, Azzedine H, Benomar A, Durosier G, Ente D, Muriel MP, Ruberg M, Slassi I, Yahyaoui M, Dubourg O, Ouazzani R, LeGuern E. Autosomal recessive axonal Charcot-Marie-Tooth disease (ARCMT2): phenotype-genotype correlations in 13 Moroccan families. Brain. 2007;130(Pt 4):1062–75.PubMedGoogle Scholar
  66. 66.
    Gabreëls-Festen A, van Beersum S, Eshuis L, LeGuern E, Gabreëls F, van Engelen B, Mariman E. Study on the gene and phenotypic characterisation of autosomal recessive demyelinating motor and sensory neuropathy (Charcot-Marie-Tooth disease) with a gene locus on chromosome 5q23-q33. J Neurol Neurosurg Psychiatry. 1999;66(5):569–74.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Kessali M, Zemmouri R, Guilbot A, Maisonobe T, Brice A, LeGuern E, Grid D. A clinical, electrophysiologic, neuropathologic, and genetic study of two large Algerian families with an autosomal recessive demyelinating form of Charcot-Marie-Tooth disease. Neurology. 1997;48(4):867–73.PubMedCrossRefGoogle Scholar
  68. 68.
    Tazir M, Azzedine H, Assami S, Sindou P, Nouioua S, Zemmouri R, Hamadouche T, Chaouch M, Feingold J, Vallat JM, Leguern E, Grid D. Phenotypic variability in autosomal recessive axonal Charcot-Marie-Tooth disease due to the R298C mutation in lamin A/C. Brain. 2004;127(Pt 1):154–63.PubMedCrossRefGoogle Scholar
  69. 69.
    Weis J, Claeys KG, Roos A, Azzedine H, Katona I, Schröder JM, Senderek J. Towards a functional pathology of hereditary neuropathies. Acta Theriol. 2017;133(4):493–515.Google Scholar
  70. 70.
    Dubourg O, Azzedine H, Verny C, Durosier G, Birouk N, Gouider R, Salih M, Bouhouche A, Thiam A, Mayer M, Ruberg M. Autosomal-recessive forms of demyelinating Charcot-Marie-Tooth disease. Neuromol Med. 2006;8(1–2):75–85.CrossRefGoogle Scholar
  71. 71.
    Wilmshurst JM, Ouvrier R. Hereditary peripheral neuropathies of childhood: an overview for clinicians. Neuromuscul Disord. 2011;21(11):763–75.PubMedCrossRefGoogle Scholar
  72. 72.
    Azzedine H, LeGuern E, Salih MA. Charcot-Marie-Tooth Neuropathy Type 4C. 2008 Mar 31 (Updated 2015 Oct 15]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2017. https://www.ncbi.nlm.nih.gov/books/NBK1340/
  73. 73.
    Cogli L, Piro F, Bucci C. Rab7 and the CMT2B disease. Biochem Soc Trans. 2009;37(Pt 5):1027–31.PubMedCrossRefGoogle Scholar
  74. 74.
    Bird TD. Charcot-Marie-Tooth Neuropathy Type 1. 1998 Aug 31 [Updated 2015 Mar 26]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2017. 2015. https://www.ncbi.nlm.nih.gov/books/NBK1205/
  75. 75.
    Chrestian N, McMillan H, Poulin C, Campbell C, Vajsar J. Hereditary neuropathy with liability to pressure palsies in childhood: case series and literature update. Neuromuscul Disord. 2015;25(9):693–8.PubMedCrossRefGoogle Scholar
  76. 76.
    Azzedine H, Ruberg M, Ente D, Gilardeau C, Périé S, Wechsler B, Brice A, LeGuern E, Dubourg O. Variability of disease progression in a family with autosomal recessive CMT associated with a S194X and new R310Q mutation in the GDAP1 gene. Neuromuscul Disord. 2003;13(4):341–6.PubMedCrossRefGoogle Scholar
  77. 77.
    Sevilla T, Jaijo T, Nauffal D, Collado D, Chumillas MJ, Vilchez JJ, Muelas N, Bataller L, Domenech R, Espinós C, Palau F. Vocal cord paresis and diaphragmatic dysfunction are severe and frequent symptoms of GDAP1-associated neuropathy. Brain. 2008;131:3051–61.PubMedCrossRefGoogle Scholar
  78. 78.
    Bolino A, Levy ER, Muglia M, Conforti FL, LeGuern E, Salih MA, Georgiou DM, Christodoulou RK, Hausmanowa-Petrusewicz I, Mandich P, Gambardella A. Genetic refinement and physical mapping of the CMT4B gene on chromosome 11q22. Genomics. 2000;63(2):271–8.PubMedCrossRefGoogle Scholar
  79. 79.
    Bolino A, Muglia M, Conforti FL, et al. Charcot-Marie-Tooth type4B is caused by mutations in the gene encoding myotubularin-related protein 2. Nat Genet. 2000;25:17–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Salih MA, Maisonobe T, Kabiraj M, Al Rayess M, Al-Turaiki MH, Akbar M, Tahan A, Urtizberea JA, Hamadouche T, Guilbot A, Brice A. Autosomal recessive hereditary neuropathy with focally folded myelin sheaths and linked to chromosome 11q23: a distinct and homogeneous entity. Neuromuscul Disord. 2000;10(1):10–5.PubMedCrossRefGoogle Scholar
  81. 81.
    Azzedine H, Bolino A, Taïeb T, Birouk N, Di Duca M, Bouhouche A, Benamou S, Mrabet A, Hammadouche T, Chkili T, Gouider R, Ravazzolo R, Brice A, Laporte J, LeGuern E. Mutations in MTMR13, a new pseudophosphatase homologue of MTMR2 and Sbf1, in two families with an autosomal recessive demyelinating form of Charcot-Marie-Tooth disease associated with early-onset glaucoma. Am J Hum Genet. 2003;72(5):1141–53.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Alazami AM, Alzahrani F, Bohlega S, Alkuraya FS. SET binding factor 1 (SBF1) mutation causes Charcot-Marie-tooth disease type 4B3. Neurology. 2014;82:1665–6.PubMedCrossRefGoogle Scholar
  83. 83.
    Siskind CE, Panchal S, Smith CO, Feely SM, Dalton JC, Schindler AB, Krajewski KM. A review of genetic counseling for Charcot Marie Tooth disease (CMT). J Genet Couns. 2013;22(4):422–36.  https://doi.org/10.1007/s10897-013-9584-4. Epub 2013 April 21. ReviewCrossRefPubMedGoogle Scholar
  84. 84.
    Alazami AM, Patel N, Shamseldin HE, Anazi S, Al-Dosari MS, Alzahrani F, et al. Accelerating novel candidate gene discovery in neurogenetic disorders via whole-exome sequencing of prescreened multiplex consanguineous families. Cell Rep. 2015;10:148–61.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Alkuraya FS. Impact of new genomic tools on the practice of clinical genetics in consanguineous populations: the Saudi experience. Clin Genet. 2013;84(3):203–8.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Azzedine H, Zavadakova P, Planté-Bordeneuve V, Vaz Pato M, Pinto N, Bartesaghi L, Zenker J, Poirot O, Bernard-Marissal N, Arnaud Gouttenoire E, Cartoni R, Title A, Venturini G, Médard JJ, Makowski E, Schöls L, Claeys KG, Stendel C, Roos A, Weis J, Dubourg O, Leal Loureiro J, Stevanin G, Said G, Amato A, Baraban J, LeGuern E, Senderek J, Rivolta C, Chrast R. PLEKHG5 deficiency leads to an intermediate form of autosomal-recessive Charcot-Marie-Tooth disease. Hum Mol Genet. 2013;22(20):4224–32.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Spagnoli C, Iodice A, Salerno GG, Frattini D, Bertani G, Fusco C. Hereditary neuropathy with liability to pressure palsies in childhood: Case series and literature update. Neuromuscul Disord. 2016;26(6):394.PubMedCrossRefGoogle Scholar
  88. 88.
    Kararizou E, Karandreas N, Davaki P, Davou R, Vassilopoulos D. Polyneuropathies in teenagers: a clinicopathological study of 45 cases. Neuromuscul Disord. 2006;16(5):304–7.PubMedCrossRefGoogle Scholar
  89. 89.
    Mehta A, Hughes DA. Fabry disease. 2002 Aug 5 [Updated 2017 Jan 5]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2017. https://www.ncbi.nlm.nih.gov/books/NBK1292/
  90. 90.
    Kraemer KH, DiGiovanna JJ. Xeroderma pigmentosum. 2003 Jun 20 [Updated 2016 Sep 29]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2017. https://www.ncbi.nlm.nih.gov/books/NBK1397/
  91. 91.
    Hijazi H, Salih MA, Hamad MH, Hassan HH, Salih SB, Mohamed KA, Mukhtar MM, Karrar ZA, Ansari S, Ibrahim N, Alkuraya FS. Pellagra-like condition is xeroderma pigmentosum/Cockayne syndrome complex and niacin confers clinical benefit. Clin Genet. 2014;87(1):56–61.CrossRefGoogle Scholar
  92. 92.
    Natale V, Raquer H. Xeroderma pigmentosum-Cockayne syndrome complex. Orphanet J Rare Dis. 2017;12:65.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Chessa L, Micheli R, Molinaro A. Focusing new ataxia telangiectasia therapeutic approaches. J Rare Dis Diagn Ther. 2016;2:2.Google Scholar
  94. 94.
    Fernet M, Gribaa M, Salih MA, Seidahmed MZ, Hail J, Koenig M. Identification and functional consequences of a novel MRE11 mutation affecting 10 Saudi Arabian patients with the ataxia telangiectasia-like disorder. Hum Mol Genet. 2005;14:307–18.PubMedCrossRefGoogle Scholar
  95. 95.
    Takashima H, Boerkoel CF, John J, Saifi GM, Salih MA, Armstrong D, Mao Y, Quiocho FA, Roa BB, Nakagawa M, Stockton DW. Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy. Nat Genet. 2002;32(2):267–72.PubMedCrossRefGoogle Scholar
  96. 96.
    Anheim M, Monga B, Fleury M, Charles P, Barbot C, Salih M, Delaunoy JP, Fritsch M, Arning L, Synofzik M, Schöls L. Ataxia with oculomotor apraxia type 2: clinical, biological and genotype/phenotype correlation study of a cohort of 90 patients. Brain. 2009;132(Pt 10):2688–98.PubMedCrossRefGoogle Scholar
  97. 97.
    Ramchandren S. Charcot-Marie-Tooth disease and other genetic polyneuropathies. Continuum (Minneap Minn). 2017;23(5):1360–77.Google Scholar
  98. 98.
    Salih MA, Mundwiller E, Khan AO, AlDrees A, Elmalik SA, Hassan HH, Al-Owain M, Alkhalidi HM, Katona I, Kabiraj MM, Chrast R, Kentab AY, Alzaidan H, Rodenburg RJ, Bosley TM, Weis J, Koenig M, Stevanin G, Azzedine H. New findings in a global approach to dissect the whole phenotype of PLA2G6 gene mutations. PLoS One. 2013;8(10):e76831.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Rossor AM, Evans MR, Reilly MM. A practical approach to the genetic neuropathies. Pract Neurol. 2015;15(3):187–98.PubMedCrossRefGoogle Scholar
  100. 100.
    Vallat JM, Funalot B, Magy L. Nerve biopsy: requirements for diagnosis and clinical value. Acta Neuropathol. 2011;121(3):313–26.PubMedCrossRefGoogle Scholar
  101. 101.
    Liao JP, Waclawik AJ. Nerve root hypertrophy in CMT type 1A. Neurology. 2004;62(5):783.PubMedCrossRefGoogle Scholar
  102. 102.
    Goedee HS, Brekelmans GJ, van Asseldonk JT, Beekman R, Mess WH, Visser LH. High resolution sonography in the evaluation of the peripheral nervous system in polyneuropathy—a review of the literature. Eur J Neurol. 2013;20(10):1342–51.PubMedCrossRefGoogle Scholar
  103. 103.
    Walker FO. Ultrasonography in peripheral nervous system diagnosis. Continuum (Minneap Minn). 2017;23(5):1276–94.Google Scholar
  104. 104.
    Gaeta M, Mileto A, Mazzeo A, Minutoli F, Di Leo R, Settineri N, et al. MRI findings, patterns of disease distribution, and muscle fat fraction calculation in five patients with Charcot-Marie-Tooth type 2 F disease. Skeletal Radiol. 2012;41(5):515–24.PubMedCrossRefGoogle Scholar
  105. 105.
    Kuhlenbäumer G, Timmerman V, Bomont P. Giant axonal neuropathy. 2003 Jan 9 [Updated 2014 Oct 9]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2017. https://www.ncbi.nlm.nih.gov/books/NBK1136/
  106. 106.
    Rudnik-Schöneborn S, Auer-Grumbach M, Senderek J. Hereditary neuropathies: update 2017. Neuropediatrics. 2017;48(4):282–93.PubMedCrossRefGoogle Scholar
  107. 107.
    Salih MA, Ahlsten G, Stålberg E, Schmidt R, Sunnegårdh J, Michaelsson M, Gamstorp I. Friedreich’s ataxia in 13 children: presentation and evolution with neurophysiologic, electrocardiographic, and echocardiographic features. J Child Neurol. 1990;5(4):321–6.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Fridman V, Bundy B, Reilly MM, Pareyson D, Bacon C, Burns J, Day J, Feely S, Finkel RS, Grider T, Kirk CA. CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis. J Neurol Neurosurg Psychiatry. 2015;86(8):873–8.PubMedCrossRefGoogle Scholar
  109. 109.
    Anazi S, Maddirevula S, Faqeih E, Alsedairy H, Alzahrani F, Shamseldin HE, et al. Clinical genomics expands the morbid genome of intellectual disability and offers a high diagnostic yield. Mol Psychiatry. 2017;22(4):615–24.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Anazi S, Maddirevula S, Salpietro V, Asi YT, Alsahli S, Alhashem A, et al. Expanding the genetic heterogeneity of intellectual disability. Hum Genet. 2017;136(11–12):1419–29.PubMedCrossRefGoogle Scholar
  111. 111.
    Monies D, Abouelhoda M, AlSayed M, Alhassnan Z, Alotaibi M, Kayyali H, et al. The landscape of genetic diseases in Saudi Arabia based on the first 1000 diagnostic panels and exomes. Hum Genet. 2017;9:1–9.Google Scholar
  112. 112.
    Maystadt I, Zarhrate M, Leclair-Richard D, Estournet B, Barois A, Renault F, Routon MC, Durand MC, Lefebvre S, Munnich A, Verellen-Dumoulin C, Viollet L. A gene for an autosomal recessive lower motor neuron disease with childhood onset maps to 1p36. Neurology. 2006;67:120–4.PubMedCrossRefGoogle Scholar
  113. 113.
    Maystadt I, Rezsöhazy R, Barkats M, Duque S, Vannuffel P, Remacle S, Lambert B, Najimi M, Sokal E, Munnich A, Viollet L, Verellen-Dumoulin C. The nuclear factor κB-activator gene PLEKHG5 is mutated in a form of autosomal recessive lower motor neuron disease with childhood onset. Am J Hum Genet. 2007;81:67–76.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Dowling JJ, Gonorazky HD, Cohn RD, Campbell C. Treating pediatric neuromuscular disorders: the future is now. Am J Med Genet A. 2018;176(4):804–41.PubMedCrossRefGoogle Scholar
  115. 115.
    Pareyson D, Saveri P, Pisciotta C. New developments in Charcot–Marie–Tooth neuropathy and related diseases. Curr Opin Neurol. 2017;30(5):471–80.PubMedCrossRefGoogle Scholar
  116. 116.
    Lee H-S, Kim MJ, Ko DS, Jeon EJ, Kim JY, Kang IS. Preimplantation genetic diagnosis for Charcot-Marie-Tooth disease. Clin Exp Reprod Med. 2013;40(4):163–8.  https://doi.org/10.5653/cerm.2013.40.4.163.CrossRefPubMedPubMedCentralGoogle Scholar
  117. 117.
    Dyck PJ. Neuronal atrophy and degeneration predominantly affecting peripheral sensory and autonomic neurons. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF, editors. Peripheral neuropathy. Philadelphia: W.B. Saunders; 1993. p. 1065–93.Google Scholar
  118. 118.
    Davidson G, Murphy S, Polke J, Laura M, Salih M, Muntoni F, Blake J, Brandner S, Davies N, Horvath R, Price S. Frequency of mutations in the genes associated with hereditary sensory and autonomic neuropathy in a UK cohort. J Neurol. 2012;259(8):1673–85.PubMedPubMedCentralCrossRefGoogle Scholar
  119. 119.
    Mroczek M, Kabzińska D, Kochański A. Molecular pathogenesis, experimental therapy and genetic counseling in hereditary sensory neuropathies. Acta Neurobiol Exp. 2014;75(2):126–43.Google Scholar
  120. 120.
    Othman SA, Malik AA. Congenital insensitivity to pain with anhidrosis in Sudanese children. Sudanese J Paediatr. 2016;16(2):80–5.Google Scholar
  121. 121.
    Pérez-López LM, Cabrera-González M, Gutiérrez-de la Iglesia D, Ricart S, Knörr-Giménez G. Update review and clinical presentation in congenital insensitivity to pain and anhidrosis. Case Rep Pediatr. 2015;2015:589852.PubMedPubMedCentralGoogle Scholar
  122. 122.
    Houlden H, King R, Blake J, Groves M, Love S, Woodward C, Hammans S, Nicoll J, Lennox G, O'Donovan DG, Gabriel C. Clinical, pathological and genetic characterization of hereditary sensory and autonomic neuropathy type 1 (HSAN I). Brain: a journal of neurology. 2006;129(Pt 2):411–25.CrossRefGoogle Scholar
  123. 123.
    Chen Y-C, Auer-Grumbach M, Matsukawa S, Zitzelsberger M, Themistocleous AC, Strom TM, Samara C, Moore AW, Cho LT-Y, Young GT, Weiss C, Schabhuttl M, et al. Transcriptional regulator PRDM12 is essential for human pain perception. Nat Genet. 2015;47:803–8.PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Kurth I. Hereditary sensory and autonomic neuropathy type II. 2010 Nov 23 [Updated 2015 Feb 19]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2017. https://www.ncbi.nlm.nih.gov/books/NBK49247/
  125. 125.
    Edvardson S, Cinnamon Y, Jalas C, Shaag A, Maayan C, Axelrod FB, Elpeleg O. Hereditary sensory autonomic neuropathy caused by a mutation in dystonin. Ann Neurol. 2012;71:569–72.PubMedCrossRefGoogle Scholar
  126. 126.
    Leipold E, Liebmann L, Korenke GC, Heinrich T, Giesselmann S, Baets J, Ebbinghaus M, Goral RO, Stodberg T, Hennings JC, Bergmann M, Altmuller J, et al. A de novo gain-of-function mutation in SCN11A causes loss of pain perception. Nat Genet. 2013;45:1399–404.PubMedCrossRefGoogle Scholar
  127. 127.
    Zhang S, Sharif SM, Chen Y-C, Valente E-M, Ahmed M, Sheridan E, Bennett C, Woods G. Clinical features for diagnosis and management of patients with PRMD12 congenital insensitivity to pain. J Med Genet. 2016;53:533–5.PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Bouhouche A, Benomar A, Bouslam N, Chkili T, Yahyaoui M. Mutation in the epsilon subunit of the cytosolic chaperonin-containing t-complex peptide-1 (Cct5) gene causes autosomal recessive mutilating sensory neuropathy with spastic paraplegia. J Med Genet. 2006;43(5):441–3.  https://doi.org/10.1136/jmg.2005.039230.CrossRefPubMedPubMedCentralGoogle Scholar
  129. 129.
    Lee MJ, Stephenson DA, Groves MJ, Sweeney MG, Davis MB, An SF, Houlden H, Salih MA, Timmerman V, de Jonghe P, Auer-Grumbach M. Hereditary sensory neuropathy is caused by a mutation in the delta subunit of the cytosolic chaperonin-containing t-complex peptide-1 (Cct4) gene. Hum Mol Genet. 2003;12(15):1917–25.PubMedCrossRefGoogle Scholar
  130. 130.
    Axelrod FB, Gold-von SG. Hereditary sensory and autonomic neuropathies: types II, III, and IV. Orphanet J Rare Dis. 2007;2:39.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Division of Pediatric Neurology, Department of Pediatrics, College of Medicine and King Khalid University HospitalKing Saud UniversityRiyadhSaudi Arabia
  2. 2.Institute for Neuropathology, Uniklinik-RWTHAachenGermany

Personalised recommendations